Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
The website presents official information for a Chinese pharmaceutical company. Its content centers on the goal of “becoming a respected and outstanding pharmaceutical enterprise,” with business areas covering antiviral drugs, human-derived proteins, general pharmaceutical formulations, in vitro diagnostics, R&D pipelines, manufacturing bases, business partnerships, and investor relations. The page discloses its STAR Market stock code as 688488 and highlights its technical capabilities in innovative anti-HIV drugs and human-derived proteins.
The site mainly serves three purposes: a corporate website, a product showcase, and an investor relations portal. On the product side, it focuses on Ainuoweilin Tablets / Aibonde®, human-derived protein products, Senna Leaf Granules, Changfukang®, and HIV diagnostic equipment and reagents. The R&D and production sections mention China’s national “Major New Drug Creation” project, patent counts, resin online adsorption technology, and production bases in Ganquan, Liuzhuang, Wuqiao, and Chahe. The news section highlights cooperation updates with organizations such as China AIDS Association, PharmaBlock Sciences, PerkinElmer, and China Healthcare Security.
The official website does not provide retail drug prices, hospital procurement prices, or quotes for partnership services. Because its core products are prescription drugs and medical-channel products, actual pricing is typically affected by national medical insurance policies, centralized procurement, hospital access, distribution systems, and prescription scenarios. The page notes that Aibonde® has been included in the National Reimbursement Drug List, which is positive for patient accessibility and commercialization, but this should not be interpreted as a specific end-user price.
The main strength is its clear business focus, building an integrated “diagnosis and treatment” narrative around HIV treatment and diagnostics. It also has the backing of a listed company, manufacturing bases, and descriptions of proprietary processes, making it more credible than a typical marketing site. The drawbacks are also obvious: the captured page title contains abnormal wording such as “leyu,” suggesting possible brand or page contamination, which undermines the seriousness of an official website; much of the news content appears to stop around 2021–2022, indicating insufficient updates; and patient-facing information such as drug leaflets, safe-use guidance, consultation channels, and drug availability is not sufficiently complete.
The site is suitable for medical institutions, pharmaceutical distributors, R&D partners, investors, industry researchers, and job seekers. General patients may use it to understand the company and its drug focus areas, but should not treat the website content as a substitute for medical advice from a doctor.
Judging by its content and business entity, the site targets the Chinese market, with complete Chinese-language pages and generally direct access from China. However, if domain resolution issues or abnormal page titles persist, users should cross-check authenticity through official announcements, stock exchange disclosures, or drug regulatory databases.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on airplanes-group.com official site.
airplanes-group.com is an China gambling provider. TG4G tracks its product information, an overall rating of 1.0/10, and a China-accessibility score of Unknown. Click "Visit Official Site" to reach airplanes-group.com directly.